Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 17:01 ET | Source: Femasys Inc.

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full...
March 27, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025...
March 19, 2025 09:20 ET | Source: Femasys Inc.

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

ATLANTA, March 19, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of...
February 11, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...
February 04, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...
January 16, 2025 08:30 ET | Source: Femasys Inc.

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq:...
March 20, 2024 08:15 ET | Source: Femasys Inc.

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

-- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI)...